{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:33:34Z","timestamp":1781825614874,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.amjcard.2019.08.016","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:48:22Z","timestamp":1573847302000},"page":"1669-1673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors (The Mayo Clinic Experience)"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-8037","authenticated-orcid":false,"given":"Ohad","family":"Oren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Kludtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.08.016_bib0001","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.08.016_bib0002","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.08.016_bib0003","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjcard.2019.08.016_bib0004","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.08.016_bib0005","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.08.016_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011246","article-title":"PCSK9 inhibitor use in the real world: data from the national patient-centered research network","volume":"8","author":"Chamberlain","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2019.08.016_bib0007","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/03007995.2018.1532885","article-title":"Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom","volume":"35","author":"Tai","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2019.08.016_bib0008","doi-asserted-by":"crossref","first-page":"e12439","DOI":"10.1111\/1755-5922.12439","article-title":"Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: two-year experience of a regional lipid clinic","volume":"36","author":"Zafrir","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.amjcard.2019.08.016_bib0009","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/clc.22713","article-title":"PCSK9 inhibitor access barriers\u2014issues and recommendations: Improving the access process for patients, clinicians and payers","volume":"40","author":"Baum","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2019.08.016_bib0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacl.2017.04.120","article-title":"Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association","volume":"11","author":"Cohen","year":"2017","journal-title":"J Clin Lipidol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919309580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919309580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:31:32Z","timestamp":1757572292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919309580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0002914919309580"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.08.016","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors (The Mayo Clinic Experience)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}